Hansa Biopharma AB (publ) (HNSBF)
- Previous Close
2.9300 - Open
2.9300 - Bid --
- Ask --
- Day's Range
2.9300 - 2.9300 - 52 Week Range
2.2570 - 5.2950 - Volume
150 - Avg. Volume
19 - Market Cap (intraday)
154.328M - Beta (5Y Monthly) 1.26
- PE Ratio (TTM)
-- - EPS (TTM)
-1.4700 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD); AskBio to evaluate imlifidase as a pre-treatment in pompe disease; and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
www.hansabiopharma.comRecent News: HNSBF
Performance Overview: HNSBF
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HNSBF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HNSBF
Valuation Measures
Market Cap
132.14M
Enterprise Value
169.39M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
10.12
Price/Book (mrq)
--
Enterprise Value/Revenue
1.02
Enterprise Value/EBITDA
-0.24
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-41.07%
Return on Equity (ttm)
-4,176.67%
Revenue (ttm)
165.88M
Net Income Avi to Common (ttm)
-844.88M
Diluted EPS (ttm)
-1.4700
Balance Sheet and Cash Flow
Total Cash (mrq)
541.47M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-485.58M
Company Insights: HNSBF
HNSBF does not have Company Insights